Skip to main content
. Author manuscript; available in PMC: 2020 Feb 16.
Published in final edited form as: Bone Joint J. 2019 Jul;101-B(7 SUPPLE C):108–114. doi: 10.1302/0301-620X.101B7.BJJ-2018-1473.R1

Fig. 4.

Fig. 4

a) Anti-vascular endothelial growth factor receptor (VEGFR) treatment decreased osteopontin (OPN) and osterix (OSX) in peri-implant tissue at two weeks post-implantation. b) The treatment also decreased OPN in tissue on implant surface at four weeks. c) Representative image of tissue on implant surface. Scale bar: 250 μm. DAPI, diamidino-2-phenylindole.